ACCL2031, A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine (IND# 149832) for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors (CTMS# 22-0131)
Lay Description
Category
- Cancers and Other Neoplasms
- Child Health
- Nervous System
- IRB Number
- 20220699HU
- NCT Number
- ct.gov registration not required
- Open to Enrollment
- Not set
Eligibility
- Eligible Ages
- Eligible Genders
- Accepts Healthy Volunteers
Inclusion Criteria
Exclusion Criteria
Study Design
Arm Groups
Study Contact
Virginia Diaz
(210) 562-9149
diazvr@uthscsa.edu
Jaclyn Hung
+1 (210) 450-5358
hungj@uthscsa.edu
Anne-Marie Langevin
(210) 567-7460
langevin@uthscsa.edu
Virginia Diaz
(210) 562-9149
diazvr@uthscsa.edu
Jaclyn Hung
+1 (210) 450-5358
hungj@uthscsa.edu
Anne-Marie Langevin
(210) 567-7460
langevin@uthscsa.edu
Principal Investigator
Anne-Marie Langevin